Does OLAPARIB Cause Haematotoxicity? 143 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 143 reports of Haematotoxicity have been filed in association with OLAPARIB (Lynparza). This represents 0.8% of all adverse event reports for OLAPARIB.
143
Reports of Haematotoxicity with OLAPARIB
0.8%
of all OLAPARIB reports
4
Deaths
14
Hospitalizations
How Dangerous Is Haematotoxicity From OLAPARIB?
Of the 143 reports, 4 (2.8%) resulted in death, 14 (9.8%) required hospitalization, and 3 (2.1%) were considered life-threatening.
Is Haematotoxicity Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for OLAPARIB. However, 143 reports have been filed with the FAERS database.
What Other Side Effects Does OLAPARIB Cause?
Death (4,378)
Malignant neoplasm progression (1,862)
Nausea (1,582)
Anaemia (1,455)
Fatigue (1,437)
Off label use (777)
Vomiting (642)
Drug ineffective (563)
Diarrhoea (514)
Asthenia (491)
What Other Drugs Cause Haematotoxicity?
CYCLOPHOSPHAMIDE (1,410)
DOXORUBICIN (1,180)
VINCRISTINE (1,038)
RITUXIMAB (812)
CARBOPLATIN (803)
METHOTREXATE (799)
PREDNISONE (730)
CYTARABINE (701)
ETOPOSIDE (677)
CISPLATIN (668)
Which OLAPARIB Alternatives Have Lower Haematotoxicity Risk?
OLAPARIB vs OLARATUMAB
OLAPARIB vs OLECLUMAB
OLAPARIB vs OLIVE OIL\SOYBEAN OIL
OLAPARIB vs OLMESARTAN
OLAPARIB vs OLMESARTAN MEDOXOMIL